Global Atazanavir Market Growth 2022-2028
SKU ID : LPI-20420209 | Publishing Date : 08-Mar-2022 | No. of pages : 98
The United States Atazanavir market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Atazanavir market, reaching US$ million by the year 2028. As for the Europe Atazanavir landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Atazanavir players cover Bristol-Myers Squibb, TEVA, Cipla, and Mylan, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Atazanavir market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
150 mg Capsule
200 mg Capsule
300 mg Capsule
50 mg Oral Powder
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Adults
Children 3 months of age and older
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Bristol-Myers Squibb
TEVA
Cipla
Mylan
Aurobindo Pharma
Emcure
Frequently Asked Questions
- By product type
- By End User/Applications
- By Technology
- By Region